Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 17, 2016 05:00 ET | Source: Affimed NV

Affimed to Present at the UBS Global Healthcare Conference -- New York

HEIDELBERG, Germany, May 17, 2016 (GLOBE NEWSWIRE) -- Affimed (Nasdaq:AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the UBS Global Healthcare Conference –...
March 30, 2016 07:30 ET | Source: Affimed NV

Affimed Reports Financial Results for Fourth Quarter and Year End 2015

HEIDELBERG, Germany, March 30, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer...
February 29, 2016 05:07 ET | Source: Affimed NV

Affimed to Present at the Cowen and Company 36th Annual Health Care Conference

HEIDELBERG, Germany, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer...
January 25, 2016 05:00 ET | Source: Affimed NV

Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA(R) (pembrolizumab) for Patients with Hodgkin Lymphoma

HEIDELBERG, Germany, Jan. 25, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer...
December 01, 2015 05:00 ET | Source: Affimed NV

Affimed to Present at the Oppenheimer 26th Annual Healthcare Conference -- New York

HEIDELBERG, Germany, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the Oppenheimer 26th Annual Healthcare...
November 11, 2015 05:00 ET | Source: Affimed NV

Affimed CEO to Present at the Jefferies 2015 Global Healthcare Conference -- London

HEIDELBERG, Germany, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the Jefferies Autumn 2015 Global...
November 05, 2015 09:28 ET | Source: Affimed NV

Affimed to Present Data on NK- and T-Cell Engagers at ASH

Heidelberg, Germany, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that...
October 14, 2015 16:07 ET | Source: Affimed NV

Affimed Announces Significant Investment by an Existing Shareholder

HEIDELBERG, Germany, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that an...
June 30, 2015 05:00 ET | Source: Affimed NV

Affimed Added to Russell 2000(R) Index

HEIDELBERG, Germany, June 30, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer...
June 17, 2015 05:04 ET | Source: Affimed NV

AbCheck and Pierre Fabre Pharmaceuticals Enter Into Strategic Research Partnership

HEIDELBERG, Germany, June 17, 2015 (GLOBE NEWSWIRE) -- AbCheck s.r.o, a wholly owned subsidiary of Affimed N.V., Heidelberg, Germany, and Pierre Fabre Pharmaceuticals announced today that they have...